It enhances chemosensitivity in SCLC by suppressing autophagy, positioning it as a therapeutic target for drug‐resistant SCLC.[16] Beyond tumor metabolism, PFKFB4 modulates immune responses through glycolysis‐dependent cytokine regulation.[17] Notably, a co‐delivery system combining rapamycin, anti‐PFKFB4 siRNA, and AS1411 aptamer demonstrated dual therapeutic and immunomodulatory effects, underscoring PFKFB4's potential in combinatorial cancer therapy.[18] However, the relationship between PFKFB4 and the immune microenvironment of SCLC requires further investigation. The gene discussed is PFKFB4; the disease is small cell lung carcinoma.